$LGVN News

Longeveron Announces Engagement of Lucid Capital Markets

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Longeveron ELPIS II Trial Did Not Meet Primary Efficacy Endpoint

Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

LGVN Posts Disappointing Trial Results

Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Announces 1-for-10 Reverse Stock Split, Expected To Become Effective August 26

Longeveron (LGVN) Q2 2026 Earnings Call Transcript

Longeveron Appoints Nirav Jhaveri CFO, Succeeding Marie Washburn

LGVN at a Major Inflection Point

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

Longeveron Inc. Q2 2026 Earnings Call Summary

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Longeveron Q2 EPS $(0.19) Misses $(0.17) Estimate, Sales $287.000K Miss $334.000K Estimate